Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SC1011 in Healthy Volunteers
NCT06160440Phase 1Completed
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sufenidone in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Guangzhou JOYO Pharma. Primary endpoint: Incidence and severity of adverse events and serious adverse events related drug up to 7 days. Started Jun 2021; status: completed.
02
Drugs
sufenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06160440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160440.